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Abstract: We tested the hypothesis that large areas of small hard drusen (diameter <63 µm) 
and intermediate drusen (diameter 63–124 µm) are associated with the incidence of  
age-related macular degeneration (AMD). Eyes of 3344 older adults with at least two 
consecutive visits spaced five years apart over a 20-year period were included. A 6-level 
severity scale, including no drusen, four levels of increasing area (from minimal  
(<2596 µm²) to large (>9086 µm²)) of only small hard drusen, and intermediate drusen, 
was used. The five-year incidence of AMD was 3% in eyes at the start of the interval with 
no, minimal, small, and moderate areas of only small drusen and 5% and 25% for eyes 
with large area of only small drusen and intermediate drusen, respectively. Compared to 
eyes with a moderate area of small drusen, the odds ratio (OR) of developing AMD in eyes 
with a large area of only small drusen was 1.8 (p < 0.001). Compared to eyes with large 
area of only small drusen, eyes with intermediate drusen had an OR of 5.5 (p < 0.001) of 
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developing AMD. Our results are consistent with our hypothesis that large areas of only 
small drusen are associated with the incidence of AMD. 
Keywords: age-related macular degeneration; epidemiology; genetic risk; incidence;  
retinal drusen; risk factors; size and area 
 
1. Introduction 
Age-related macular degeneration (AMD) is a complex chronic disease affecting multiple layers of 
the retina. Histologically, its earliest subclinical stages have been defined by the presence of  
age-related thickening of Bruch membrane with calcifications and basal laminar deposits prior to the 
appearance of hard and soft drusen in the macula as detected by ophthalmoscopy [1]. Clinically, its 
earliest stages are often defined by the presence of large soft drusen (≥125 µm in diameter) [2,3]. 
Progression of AMD involves the appearance of increasing numbers of large soft distinct and indistinct 
drusen that may become confluent, as well as the development of pigmentary abnormalities 
(depigmentation and increased retinal pigment) of the retinal pigment epithelium (RPE) in the macula. 
Progression rates vary, with some eyes remaining in early stages of the disease over long periods of 
time while others progress more rapidly to the late stages of the disease, geographic atrophy and 
neovascular AMD. Reduction in choroidal perfusion and retinal tissue oxygenation levels, increased 
systemic inflammation, presence of atherosclerosis, and elastic tissue degeneration have been 
hypothesized to be involved in the pathogenesis of AMD [3,4]. Genes associated with the alternative 
complement system, lipid metabolism, atherosclerosis, and other pathways have been found to be 
associated with the development of late AMD [5,6]. 
Labeling an eye as having early AMD has been based on empirical evidence from epidemiological 
studies (e.g., the Beaver Dam Eye Study, the Rotterdam Study, the Blue Mountains Eye Study), 
clinical trials, such as the Age-Related Eye Disease Study (AREDS) and observations of clinical  
cohorts [2,3,7–12]. In those studies, the presence of large drusen (≥125 µm in diameter) in one or both 
eyes increased the risk of developing signs of late AMD [2,3,11]. In the AREDS, the presence of 
intermediate drusen (between 63 and 124 µm in diameter) in both eyes was also associated with a 
small but significant increase in risk of developing late AMD [2,11]. Presence of a few small hard 
drusen is common and is not thought to be an early stage of AMD [13,14]. Eyes with a larger area of 
only small hard drusen (>9086 µm2) compared with eyes with a smaller drusen area (<2596 µm²) 
involving the macula have been found to be associated with increased age-adjusted 15-year cumulative 
incidence of soft indistinct drusen (16.3% vs. 4.7%) and pigmentary abnormalities (10.6% vs. 2.7%) [7]. 
These findings suggested that a larger area of small hard drusen in the absence of larger soft drusen or 
other retinal AMD lesions in an eye might be an even earlier clinical stage of AMD than that which is 
currently defined by the presence of larger drusen. 
We hypothesized that larger areas of only small hard drusen and the presence of intermediate drusen 
were related to the incidence of AMD. We also hypothesized that age, sex, and two specific  
single-nucleotide polymorphisms (SNPs), one in the complement factor H region (CFH Y402H 
rs1061170) on chromosome 1 and the other in the age-related maculopathy susceptibility 2 region 
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(ARMS2 A69S rs10490924) on chromosome 10, were related to the incidence of increasing areas of 
small hard drusen and to intermediate drusen. Longitudinal data over a 20-year period from the Beaver 
Dam Eye Study were used in the analyses. 
2. Experimental Section 
2.1. Study Population 
Identification and descriptions of the population in the Beaver Dam Eye Study have appeared in 
previous reports [15–20]. In brief, a private census identified 5924 persons living in the city and 
township of Beaver Dam, Wisconsin aged 43–86 years, of which 4926 participated in the baseline 
examination in 1988–1990 and in up to four follow-up examinations in 1993–1995, 1998–2000,  
2003–2005 and 2008–2010. Over 99% of the population was white. All subjects gave their informed 
consent for inclusion before they participated in the study. The investigations were carried out 
following the rules of the Declaration of Helsinki, and the research protocol was approved by the 
institutional review board at the University of Wisconsin-Madison. Comparisons between participants 
and nonparticipants at each examination have appeared elsewhere [15–20]. In general, those who 
participated in a follow-up examination over the 20-year period of the study were more likely to be 
younger than nonparticipants who were alive or those who died before follow-up and, with adjustment 
for age, were less likely to have early AMD as defined as having severity level 20 or greater on the  
5-step Three Continent Consortium AMD severity scale in at least 1 eye [9]. 
2.2. Procedures 
The baseline and follow-up examinations used similar procedures, which have been described in 
detail elsewhere [2,4,13,21–27]. Stereoscopic 30° color film fundus photographs centered on the disc 
(Diabetic Retinopathy Study standard field 1) and macula (Diabetic Retinopathy Study standard field 2) 
and a nonstereoscopic color fundus photograph temporal to but including the fovea of each eye were 
obtained. Details of the grading procedure have been described elsewhere [2,4,13,21–27]. 
2.3. Genetic Measurements 
The genetic measurements have been described in detail elsewhere [28]. In brief, samples of DNA 
were extracted from buffy coat specimens collected at the baseline examination. The two SNPs most 
commonly associated with AMD, Y402H in CFH (rs1061170) and A69S in ARMS2 (rs10490924), 
were used in this study. For CFH, T was considered the wild allele and C the risk allele; for ARMS2, 
G was considered the wild allele and T the risk allele. 
2.4. Definitions 
Age was documented at each participant visit and was categorized as <60 years, 60–69 years, or  
≥70 years. Body mass index was calculated by dividing a participant’s weight in kilograms by his or 
her height in meters squared. Current heavy drinking was defined as the consumption of 4 or more 
servings of alcoholic beverages daily at the time of the examination; a serving was defined as 12 fluid 
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ounces of beer, 4 fluid ounces of wine, or 1.5 fluid ounces of liquor. Participants were considered 
physically active if they engaged in physical activity long enough to work up a sweat at least 3 times 
per week. Hypertension was defined as blood pressure ≥140/90 mmHg or use of anti-hypertensive 
medication. Aspirin, multivitamin, and anti-hypertensive medication use were determined from self-report. 
The severity status of drusen in an eye was defined as follows. 
 Level 1 (No drusen): No signs of any drusen or of early or late AMD. 
 Level 2 (Minimal area of small hard distinct drusen): Presence of small hard distinct drusen 
<63 µm in diameter as the largest size drusen involving a circular area of the macula of up to 
2596 µm² and no other signs of AMD. 
 Level 3 (Small area of small hard distinct drusen): Presence of small hard distinct drusen  
<63 µm in diameter as the largest size drusen involving a circular area of the macula between 
2597 µm² and 5192 µm² and no other signs of AMD. 
 Level 4 (Moderate area of small hard distinct drusen): Presence of small hard distinct 
drusen <63 µm in diameter as the largest size drusen involving a circular area of the macula 
between 5193 µm² and 9086 µm² and no other signs of AMD. 
 Level 5 (Large area of small hard distinct drusen): Presence of small hard distinct drusen  
<63 µm in diameter as the largest size drusen involving a circular area of the macula greater 
than 9086 µm² and no other signs of AMD. 
 Level 6 (Intermediate drusen): Presence of one or more drusen 63 to 124 µm in diameter as 
the largest size drusen and no other signs of AMD. 
Early AMD was defined as the presence of small to intermediate drusen, regardless of area of 
involvement, with any pigmentary abnormalities (defined as depigmentation and increased retinal pigment) 
or the presence of large drusen (≥125 µm in diameter). Late AMD was defined by the presence of 
geographic atrophy and signs of exudative AMD, such as serous detachment of the RPE and/or  
sensory retina. 
2.5. Statistical Analysis 
We examined the association of the drusen severity level in an eye and other risk factors measured 
at one examination with drusen severity level in that eye at the next examination, 5 years later. Pairs of 
visits were accumulated during the 20 years of the study and risk factors were updated for each 5-year 
period. Multiple contributions from an individual were accounted for by using generalized estimating 
equations (GEE). 
An eye was considered at risk for incidence of a specific level on the drusen severity scale if drusen 
were gradable at 2 consecutive visits and had a less severe level of drusen at the earlier examination. 
The outcome of interest was the development of drusen at or above a given severity level (e.g., 
intermediate drusen or any AMD). For example, development of intermediate drusen (Level 6) was 
evaluated for all eyes with Level 1 through Level 5 at the start of an interval. If the severity level was 
Level 6 or any AMD at the follow-up visit, the eye was considered to have developed  
intermediate drusen. 
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Analyses of specific risk factors (age, sex, genotype) were stratified by the initial drusen severity 
level. Models were adjusted for age and sex. SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) was 
used for all analyses. 
3. Results 
3.1. Participant Characteristics 
There were 3344 individuals who contributed AMD data for at least one pair of consecutive 
examinations: 3198 with baseline and five-year follow-up data, 2367 participants with five-year and  
10-year follow-up data, 1865 participants with 10-year and 15-year follow-up data, and 1468 
participants with 15-year and 20-year follow-up data. For each interval, 75%–80% of individuals had 
data available for both eyes, resulting in 15821 total person-eye-visit intervals. Table 1 shows the 
characteristics of this group. The percentages of individuals at the start of a five-year follow-up 
interval with Level 1, Level 2, Level 3, Level 4, Level 5, and Level 6 were 14%, 26%, 16%, 15%, 14% 
and 16%, respectively (Table 1). The genotype distributions for CFH Y402H were 41%, 46% and 13% 
for T/T, T/C, and C/C, respectively; the genotype distributions for ARMS2 A69S were 61%, 35%, and 
4% for G/G, G/T, and T/T, respectively. 
3.2. Incidence of Varying Areas of Small Hard Drusen, Intermediate Drusen, and Any AMD 
Figure 1 shows the distribution of drusen severity levels at the follow-up examination for each level 
at the start of the interval and Table 2 shows the results of incidence analyses for each drusen severity 
level. As severity level at the beginning of an interval increased, so did the development of the more 
severe drusen levels (Figure 1). For example, 8% of eyes with Level 1 (n = 2206) at the start of a  
five-year follow-up interval developed Level 5 or worse compared with 25% of eyes starting at Level 4 
(n = 2370). 49% of eyes with Level 1 (n = 2206) developed Level 2 or worse by the end of a five-year 
period, and 36% of eyes with Level 3 (n = 2515) developed Level 4 or worse. 
Five-year incidence of Level 6 or worse was 17%, 12%, 10%, 8%, and 7% for individuals with Level 5, 
Level 4, Level 3, Level 2, and Level 1 at the start of the interval, respectively. Incidence of any AMD 
was higher in eyes with Level 6 at the start of the interval compared to eyes with Level 5 (25% vs. 5%; 
odds ratio [OR] = 5.5) and was also higher in eyes with Level 5 vs. Level 4 at the beginning of a  
five-year period (OR = 1.8).  
J. Clin. Med. 2015, 4 430 
 
 
Table 1. Characteristics of individuals included in analyses averaged over all examination 
phases in the Beaver Dam Eye Study, 1988–1990 to 2008–2010. ARMS2, age-related 
maculopathy susceptibility 2 rs10490924; CFH, complement factor H rs1061170; SD, 
standard deviation. 
Characteristic  Person-Eye-Visits (N) Mean (SD) or %
Age, years 15821 62.3 (9.5) 
Sex 
Female 9016 57.0 
Male 6805 43.0 
Beginning drusen severity level 
Level 1 2206 13.9 
Level 2 4055 25.6 
Level 3 2515 15.9 
Level 4 2370 15.0 
Level 5 2210 14.0 
Level 6 2465 15.6 
CFH genotype 
T/T 5942 40.6 
T/C 6771 46.3 
C/C 1919 13.1 
ARMS2 genotype 
G/G 9172 60.9 
G/T 5323 35.3 
T/T 574 3.8 
Hypertension present 
No 7911 50.4 
Yes 7776 49.6 
Body mass index, kg/m² 15625 29.6 (5.6) 
Smoking history 
Never 7312 46.2 
Past 6189 39.1 
Current 2312 14.6 
Heavy drinking history 
Never 13377 84.6 
Past 2154 13.6 
Current 276 1.7 
Physical activity level 
Active 4843 30.6 
Sedentary 10969 69.4 
Using multivitamins 
No 7720 48.8 
Yes 8101 51.2 
Currently using aspirin 
No 10946 69.3 
Yes 4854 30.7 




Figure 1. The relationship of no drusen, 4 areas of increasing involvement of the macula 
by small hard drusen and intermediate drusen to the 5-year incidence of more severe levels 
of drusen and any AMD in the Beaver Dam Eye Study, 1988–1990 to 2008–2010. 
3.3. Relationships of Age, Sex and Two AMD Candidate Genes to the Five-Year Incidences of Small 
Hard Drusen, Intermediate Drusen and AMD 
Figures 2–5 and Supplementary Tables S1–S6 show the relationships between drusen severity level 
and AMD status at follow-up by age, sex and genetic information, stratified by initial drusen level. 
Figure 2 shows the distribution of the follow-up drusen severity level and AMD status by age group. 
Odds ratios for these relationships are presented in Supplementary Tables S1–S6, with each possible 
outcome in a separate table. Older age was associated with higher five-year incidence of most 
outcomes and the associations were stronger in eyes with larger areas of small hard drusen and more 
severe lesions. Sex was not associated with the development of any drusen outcome (Figure 3). 
Figures 4 and 5 and Supplementary Tables S1–S6 show the relationships of the CFH and ARMS2 
candidate genes stratified by drusen severity levels at the beginning of an interval to the five-year 
incidences for each drusen severity level and AMD outcome. While few individuals had two risk 
alleles, especially for ARMS2, the increasing incidence was still apparent and statistically significant 
for some relationships. For CFH Y402H genotype (Figure 3), the strongest associations for incidence 
of Level 6 (Supplementary Table S5) and incidence of any AMD (Supplementary Table S6) occurred 
when the initial severity was at least Level 4. Incidence of Level 6 was about 9%–10% regardless of 
the number of risk alleles for CFH Y402H (p = 0.35 for any differences after adjusting for age and sex) 
when initial drusen severity was Level 3 but ranged from 14% to 25% for 0 vs. 2 risk alleles when the 
initial severity was Level 5 (OR = 1.4 per risk allele, p < 0.001 after adjusting for age and sex). Where 
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an association with CFH was present, the association was stronger in individuals with 2 risk alleles 
compared to individuals with only one risk allele. 
Table 2. Incidence of specific level of drusen area/severity by initial severity level. N is the 
number of person-visit-eyes at risk. The p value is the Wald test for any differences 





N at Risk % Incident
Comparison 
Level 
OR (95% CI) p Value 
Level 2 or worse Level 1 2206 48.9   
Level 3 or worse 
Level 1 2206 22.8   <0.001 
Level 2 4055 37.8 Level 1 2.0 (1.8, 2.3) 
Level 4 or worse 
Level 1 2206 14.3   <0.001 
Level 2 4055 22.5 Level 1 1.7 (1.5, 1.9)  
Level 3 2515 35.5 Level 2 1.9 (1.7, 2.1)  
   Per level 1.8 (1.7, 1.9) <0.001 
Level 5 or worse 
Level 1 2206 7.9   <0.001 
Level 2 4055 11.3 Level 1 1.4 (1.2, 1.7)  
Level 3 2515 18.5 Level 2 1.7 (1.5, 2.0)  
Level 4 2370 24.5 Level 3 1.4 (1.2, 1.6)  
   Per level 1.5 (1.5, 1.6) <0.001 
Level 6 or worse 
Level 1 2206 6.8   <0.001 
Level 2 4055 7.7 Level 1 1.2 (1.0, 1.4)  
Level 3 2515 9.8 Level 2 1.3 (1.1, 1.5)  
Level 4 2370 11.6 Level 3 1.2 (1.0, 1.4)  
Level 5 2210 17.3 Level 4 1.5 (1.3, 1.8)  
   Per level 1.3 (1.2, 1.4) <0.001 
Any AMD 
Level 1 2206 3.1   <0.001 
Level 2 4055 2.5 Level 1 0.8 (0.6, 1.1)  
Level 3 2515 3.1 Level 2 1.2 (0.9, 1.6)  
Level 4 2370 2.9 Level 3 0.9 (0.7, 1.3)  
Level 5 2210 5.1 Level 4 1.8 (1.3, 2.4)  
Level 6 2465 25.2 Level 5 5.5 (4.5, 6.8)  
   Per level 1.8 (1.7, 1.9) <0.001 




Figure 2. Five-year incidence of increasing area of small hard drusen, intermediate drusen, 
and any AMD by age group (<60, 60–69, and ≥70 years) and severity level at the 
beginning of the interval. 
For ARMS2 A69S genotype (Figure 4), most of the strongest associations were for smaller areas of 
drusen at the start of an interval. Having two risk alleles was more strongly associated with incidence 
than having one risk allele present. For example, incidence of Level 6 was higher when there were two 
risk alleles compared to one or 0, but was only statistically significant when the initial level of drusen 
severity was Level 1, 2, or 3. Among individuals with Level 1, 13% of those with the T/T genotype  
(2 risk alleles), 8% of the G/T (1 risk allele) and 6% of those with G/G (0 risk alleles) developed Level 
6 over the next five years (OR = 1.7 per risk allele, p = 0.002 after adjusting for age and sex). Among 
persons with Level 5, 17%, 17% and 23% of those with 0, 1 and 2 risk alleles, respectively, developed 
Level 6 (OR = 1.2 per risk allele, p = 0.16 after adjusting for age and sex). 




Figure 3. Five-year incidence of increasing area of small hard drusen, intermediate drusen, 
and any AMD by sex and severity level at the beginning of the interval. F = female;  
M = male. 
 
Figure 4. Five-year incidence of increasing area of small hard drusen, intermediate drusen, 
and any AMD by CFH Y402H (rs1061170) genotype and severity level at the beginning of 
the interval. 




Figure 5. Five-year incidence of increasing area of small hard drusen, intermediate drusen, 
and any AMD by ARMS2 A69S (rs10490924) genotype and severity level at the beginning 
of the interval. 
4. Discussion 
There is a general consensus that large soft drusen and pigmentary abnormalities define an early 
AMD phenotype and that neovascular AMD and pure geographic atrophy define the late advanced 
AMD phenotype. However, there is less agreement regarding whether a large area of small hard 
distinct drusen defines an even earlier AMD phenotype. In the Beaver Dam Eye Study, we found that 
the incidence of increasingly larger areas of small hard drusen (more severe level) is dependent upon 
the prior less severe level (smaller area) of small hard drusen. Even an eye with a minimal area of small 
hard drusen (Level 2) has approximately 50% greater odds of progressing by one step than an eye with 
no drusen (Level 1). While there is some variability, a stepwise increase in severity seems reasonable 
to assume. Furthermore, the data are consistent with the notion that there is an increasing likelihood of 
progression to intermediate drusen or any AMD with a larger area of small hard drusen. We had 
previously reported that a large area >9086 µm²) of small hard distinct drusen compared to a small area 
(≤2596 µm²) of involvement of these drusen in the absence of any other signs of AMD was associated 
with increased 15-year cumulative incidence of early AMD (18% vs. 5%) and late AMD (1.5% vs. 
0.4%) [7]. This was consistent with earlier observations from clinical studies suggesting that eyes with 
large numbers of small hard drusen were at greater risk of developing AMD [29–31]. 
The process by which large soft drusen develop and their relation to small hard drusen is poorly 
understood [29,31–33]. Large soft drusen have been thought to result either from the aggregation of 
small hard drusen or in areas where small hard drusen appear to be absent. Hard and soft drusen have 
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differing molecular components. Sarks et al. and others [14,34,35] have described the focal 
aggregation of small hard drusen into mounds of membranous debris, which accumulate as a 
widespread shallow layer between the basement membrane of the pigment epithelium and Bruch 
membrane. Small subclinical sized drusen (<30 µm in diameter) not usually visible on 
ophthalmoscopy have been found to become confluent and form soft drusen [31]. Areas surrounding 
individual large soft drusen have been shown to contain several small merging drusen and thick basal 
laminar drusen. Further understanding of the biochemical, physiological, and anatomic changes that 
take place as large soft drusen evolve is needed. 
We wanted to examine whether age and different high risk AMD candidate genes might affect 
different stages of drusen development in addition to the natural history of drusen development. In the 
Beaver Dam Eye Study, genetic associations from CFH Y402H and ARMS2 A69S appear to affect 
different stages of drusen development. Some of these differences are related to underpowered tests 
with ARMS2 but may also represent differences in the genetic influences on disease. 
In the present report, besides the differing associations of the SNPs of two genes associated with 
AMD (CFH Y402H rs1061190 and ARMS2 A69S rs10490924), we found relationships of age but not 
sex to the incidence of increasing areas of macular involvement with small hard drusen, intermediate 
drusen, and AMD. It is difficult to compare our findings with those of other population-based studies 
that have examined the incidence and progression of small hard distinct drusen due to differences in 
the criteria defining the drusen endpoint among the studies. In the Inter99 Eye Study [36], there was no 
relationship between the presence of 20 or more small hard macular drusen with gene SNPs CFH 
Y402H, LOC387715 A69S, HTRA1 rs11200638, CFB R32Q, and CFB L9H while drusen >63 µm in 
diameter were related to CFH Y402H. The Münster Aging and Retina Study (MARS) [37] examined 
drusen features such as number, confluence, type, size, and area occupied by macular drusen in 406 
patients with early AMD and 170 healthy controls with a follow-up examination after 2.6 years. In that 
study, over a 2½ year period, CFH Y402H but not ARMS2 A69S was associated with the development 
of 20 or more small hard drusen in eyes described as healthy at baseline. In another study, investigators 
developing a new clinical classification system for AMD concluded that small drusen (<63 µm) should 
be considered to be a result of normal aging changes and that there was no clinically relevant increased 
risk of late AMD developing in these eyes [30]. In that study, persons with intermediate drusen (63 to 
124 µm in diameter) were considered to have early AMD. These findings from the Beaver Dam Eye 
Study and other studies suggest that intermediate drusen may be one of the earliest stages of AMD 
clinically identifiable by grading of fundus photographs. Others have shown an increased risk of 
developing AMD when intermediate drusen are present [30,36,37]. 
Our study has many strengths, including repeated examinations during a 20-year period that used 
detailed standardized procedures for obtaining stereoscopic color fundus photographs of the macula 
and an objective system for grading those photographs for AMD phenotypes. However, the study also 
had a number of limitations. First, the Beaver Dam Eye Study cohort is racially/ethnically 
homogeneous (over 99% white), which limits our inferences regarding these findings in nonwhites. 
Second, we used SNPs from only two AMD candidate genes; it is possible that inclusion of all the 
identified possible loci may have affected our findings. Non-AMD related processes may cause the 
development of the first few small hard macular drusen. There may also be more misclassification in 
eyes with no or only small drusen because it is more difficult to detect some small hard drusen, leading 
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to greater variability in grading their presence than in eyes with larger drusen or more severe late signs 
of AMD and resulting in detection bias due to size. Mortality may also have limited the interpretation 
of associations because of selective survival. 
5. Conclusions 
This report provides long-term population-based observations regarding the relationships of age, 
sex, and presence of risk alleles for two AMD candidate genes, CFH Y402H rs1061170 and ARMS2 
A69S rs10490924, to the incidence of small hard drusen, as well as their role in the natural history of 
AMD in its earliest clinical stages using grading of stereoscopic 30° color fundus film photography. 
The findings from the Beaver Dam Eye Study and others provide some evidence that intermediate 
drusen and large areas of small hard drusen may be early clinically detectable stages in the trajectory 
of the disease and not just risk indicators. Intervals of observation of the cohort longer than five years 
may be needed to provide enough time to evaluate the natural history of no or a few small drusen 
progressing to AMD. This will be evaluated by multistate modeling in future analyses. Our findings 
also suggest the genetic risks from CFH and ARMS2 may influence different stages of the disease in 
different ways. Inclusion of newer technological assessment tools such as spectral domain optical 
coherence tomography and autofluorescence may provide more sensitive and reliable approaches to 
detect and quantitate even earlier stages of AMD [33]. This may prove useful in the study of 
pathogenetic risk factors only associated with these earlier stages of AMD. However, risks and benefits 
of defining an individual as having early AMD when newer classifications are used in clinical practice 
will need to be examined further. 
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